In January 2026 a Chinese biotech licensed a PD-1/VEGF bispecific antibody it had discovered itself to AbbVie, selling the rights to everything outside Greater China while keeping the home market. In October, AbbVie presented trial results for the same molecule — now carried as ABBV-1480 — at ESMO, with lung cancer and other solid tumours in view. Those two facts are the whole story for an international patient reading this page: one new drug, two regulatory pipelines, and no reason to assume the clock runs at the same speed on both sides. If you are researching how to access new drugs in China before they are approved in the US or Europe, the useful question is not "is China cheaper" but "which legal route puts an unregistered or investigational medicine in front of me, and what paperwork does that route demand."
New Drugs In China Before US Approval: Why A Gap Exists At All
What an out-licence actually splits
An exclusive licence carves the world into territories, and each territory then runs its own regulatory race. The 21st Century Business Herald report describes the January 2026 agreement this way: AbbVie took exclusive development, manufacturing and commercialisation rights for RC148 in all regions outside Greater China, and the candidate is being developed there under the code ABBV-1480. Greater China is not inside that licence, which means filings, trial programmes and pricing decisions for the Chinese market stay with the originator, on a Chinese schedule. The economics show how much work both sides intend to do: a US$650 million upfront payment, eligibility for up to US$4.95 billion in development, regulatory and commercial milestones, and tiered double-digit royalties on net sales outside Greater China.
What the economics do not show is which side finishes first, and this is where most patient-side reasoning goes wrong. A domestic sponsor that keeps its home territory can prioritise its own patients and file there earlier; equally, a multinational with a far larger regulatory and manufacturing operation can shorten the overseas path. Out-licensing creates two parallel routes, not a guaranteed ordering. The durable lesson is structural rather than directional: the approval status of a medicine in your country is a weak predictor of its status in China, in either direction. So the first task for any patient is a status check on one specific molecule in one specific jurisdiction this month, not a general theory about which country moves faster.
What The ABBV-1480 News Does And Does Not Support
The verifiable content is narrow. AbbVie presented ABBV-1480 study results at ESMO in October 2026, and the reporting frames them as pointing to potential in lung cancer and other solid tumours. Nothing in that reporting states that any regulator has approved the molecule, in China or anywhere else, and an interim conference readout is not a prescribable medicine. For a patient today, RC148/ABBV-1480 is a trial question, not a prescription question: realistic contact with it would run through an open protocol, or through a named or expanded-access programme if one exists and would accept you.
The same article contains a second, more instructive datapoint for readers outside oncology. On 8 September 2026, Vor Bio announced that UPSTREAM MG, its global Phase III of telitacicept in generalised myasthenia gravis, had completed patient enrolment, with 24-week topline results expected in the first half of 2027. Telitacicept is another Chinese-origin molecule whose availability outside Greater China depends on a partner's registration programme. If your condition sits behind a Phase III that is still running, then the trial calendar — enrolment close, database lock, readout, submission, review — is what decides when your oncologist or neurologist can prescribe, and each of those steps is a month or a season you cannot buy your way past.
The Two Routes That Actually Move A Patient Toward An Unregistered Medicine
Route 1: A clinical trial with a site you can physically attend
Trials are the only route for a drug that is not approved anywhere. The gate is the protocol, not your willingness to travel: disease stage, prior lines of therapy, organ function, performance status, and the sites the sponsor has activated all filter candidates, and the investigator makes the final call. Practical consequences for an international patient are specific. Screening assumes you are physically present for cycles, scans and toxicity visits, so you are planning a stay of weeks rather than a one-week trip. Cost is split protocol-by-protocol: in many studies the investigational agent is supplied by the sponsor while hospitalisation, routine care and management of side effects are billed normally, and the exact division must be confirmed line by line with the site coordinator. Continuity after you go home — who manages a delayed immune-related reaction, who can actually obtain the drug on a re-treatment schedule — is the question most patients forget to ask before flying. Trial access is also historically how Chinese-origin cell therapies reached patients; our CAR-T therapy in China cost guide sets out how that category is priced locally.
Route 2: Boao Lecheng, where "sold abroad, not yet registered here" becomes legal
Hainan's Boao Lecheng International Medical Tourism Pilot Zone is the one place in China where a doctor can lawfully prescribe a specific medicine that is marketed overseas but has no mainland registration yet. Xinhua, citing the Economic Information Daily, reports the zone has cleared more than 620 special-permit drugs, devices and special foods across 40-plus medical institutions, cumulative benefit to more than 340,000 patients, and 863,500 medical-travel visits in the first nine months of 2026 — up 84.59% year on year, of which 10,700 visits came from outside China. Speed is the real differentiator: vorasidenib took about a month from overseas launch to permission in Lecheng (August 2024 to 30 September 2024), and lenacapavir took 8 working days. Sichuan University West China Lecheng Hospital has brought in nearly 100 overseas drugs and devices not yet approved domestically, and the zone works with partners in 20 countries and regions and more than 190 drug and device companies, with 69 foreign-invested enterprises registered, including one wholly foreign-owned hospital, the Boao Fullong Cardiovascular Hospital.
Money follows the same pattern. The report describes one special drug (listed as 科赛拉) that launched in the US in 2021 at roughly US$1,400 per vial, entered China in 2022 at about ¥5,980 per bottle, and dropped to ¥466 per vial after being added to the national medical insurance catalogue in November 2024. Ninety-six commercial insurance products now carry Lecheng special-drug cover, and the zone's global special-drug insurance product has been reissued for seven consecutive years. Note the boundary carefully: Lecheng solves a missing-Chinese-registration problem. It does not solve a never-approved-anywhere problem — ABBV-1480 is not a Lecheng case today.
Route 3: A registered-drug plan from an international medical department
Most patients who travel for "a new drug" end up here: stage re-evaluation, a second opinion, and a regimen built from what is already approved and available in China, with a trial referral if one fits. Our cancer treatment in China and hospital directory pages cover how that pathway is organised.
Timeline And Cost: Compare Before You Choose
| Route | Precondition on the drug | How long to a first dose | Cost basis | Who it suits |
|---|---|---|---|---|
| Clinical trial at a Chinese site | No approval needed anywhere, but an open protocol and an eligible arm | Set by the screening window; slots can close without notice | Agent usually sponsor-supplied; hospital care and travel billed to you — confirm in writing | Few remaining standard options, disease matching an active arm |
| Boao Lecheng special permit | Already marketed abroad, mainland registration missing | Reported as fast as 8 working days (lenacapavir) and about one month (vorasidenib) | Per-product quotation from the institution; the 科赛拉 example shows the scale of the price gap | A medicine already proven and sold elsewhere |
| Registered drug, international department | Approved in China for your indication | Earliest open appointment, per the department | Published department fees plus inpatient costs | Second opinions, staging, standard of care plus trial referral |
| Records review only | None | Fastest | Consultation and translation fees | Deciding whether travel is worth it at all |
Anything not attributed to the two reports above is quoted per institution, per product and per dose — a written quotation, not a national price list, governs your bill.
What To Have In Hand Before You Commit To Travel
Send the pathology report with the blocks or slides if they can be released; imaging as original DICOM data rather than reports alone; a dated history of every line of therapy with doses and response; and recent organ-function labs, all in a formally translated set so the Chinese physician can read it against local protocols. Then confirm the entry and booking mechanics before you fly: China's medical visa requirements vary by nationality and length of stay, and the invitation documents a hospital must issue are part of that process. Ask your own insurer, in writing, whether it will pay for an unregistered medicine received abroad — assume no cover until told otherwise. And most important, before any of this: a concrete treatment plan has to be assessed in person by a licensed physician who has examined you and reviewed the full record. Interim data changes, eligibility lists close, and nothing on this page is advice about your own case.
Where OriEast Fits
OriEast coordinates the practical layer: translation of records, appointment booking at the treating hospital — including scheduling through Shanghai hospital international departments — physician pre-review of whether a trial or a special-permit product is even plausible for your diagnosis, and coordination during your stay. Start with a case evaluation so we can look at your actual diagnosis and drug name, or send us your questions through the inquiry form. Background on organising the trip itself is in our complete medical tourism China guide.